Noopept, also written N-phenylacetyl-L-prolylglycine ethyl ester and GVS-111, is a dipeptide drug that Vakhitova and colleagues say was "designed as a drug at State Zakusov Institute of Pharmacology" in Moscow.2,3 Its authors describe the non-peptide prototype as piracetam, and a 2002 Russian review states that noopept was made by "the short-peptide design" imitation of a nonpeptide nootrope.2,4 In experiments, the 2002 review reports an effective dose "1000 times lower for noopept than for pyracetam"; the app's note also gives roughly 1000-fold potency by weight, and the review rests on experimental investigations, not on a human comparison.4 A 2016 paper from the same institute repeats "1,000 times" in its introduction, while its discussion says the effective doses of noopept are "three times lower than that of Piracetam", so the potency ratio is not stated consistently even within that paper.2 The 2002 review reports that tablets of 5 mg and 10 mg were under clinical assessment for cognitive deficiency of cerebrovascular and post-traumatic origin, and a 2018 paper from the Zakusov Research Institute says noopept "was developed and introduced into medical practice".4,5 Cohen and colleagues, in Neurology: Clinical Practice in 2021, describe omberacetam (noopept) as "a medication available in Russia" and write that analogs of piracetam are not approved by the FDA for use in the US.6 The app grades the evidence for noopept as moderate; the human studies located are Russian clinical reports whose PubMed records are short (one states 60 patients, the others give no group size), and the grade is the app's, not a conclusion of the sources.

Every mechanism statement in this section comes from rat experiments, cell work or experimental investigations whose species the record does not name, not from measurements in people.

Neurotrophin expression in rats

Ostrovskaya and colleagues at the V. V. Zakusov Institute of Pharmacology (Bulletin of Experimental Biology and Medicine, 2008) measured NGF and BDNF messenger RNA in rat hippocampus and cortex by Northern blot after a single dose or 28 days of treatment.3 In the hippocampus, mRNA for both neurotrophins rose after a single dose.3 In the cortex, expression was below control after a single dose, and chronic treatment gave "a slight increase in BDNF expression".3 The authors report that chronic treatment "was not followed by the development of tolerance, but even potentiated the neurotrophic effect", and write that these changes "probably play a role in neuronal restoration".3 The PubMed record states no dose, no group size and no funding, and the authors' statement that noopept "holds much promise to prevent the development of Alzheimer's disease in patients with mild cognitive impairment" is their suggestion, while the measurements were made in rats.3

Deeper analysis: the HIF-1 cell study (Vakhitova 2016)

Vakhitova and colleagues (Acta Naturae, 2016) tested noopept in HEK293 cells, a human embryonic kidney cell line, transfected with luciferase reporters for nine transcription factors, and ran molecular docking.2 At 10 μM, noopept "increase[d] the DNA-binding activity of HIF-1 only", with no effect on the other eight factors, and the effect was concentration-dependent.2 Piracetam at 1 mM "failed to affect significantly any of the TF under study".2 The results section of the same paper gives piracetam concentrations of 10 μM (data not shown) and 1 μM, which differs from the 1 mM given in the paper's summary section.2 Docking suggested that the L-isomer of noopept and one metabolite can bind the active site of prolyl hydroxylase 2, unlike the pharmacologically ineffective D-isomer.2 The authors "propose the HIF-positive effect as the primary mechanism", and they state that a screen of noopept against more than 100 known receptors, run by the CEREP company, did not give the expected identification of primary targets.2 The paper lists earlier findings by its own group, including "choline-positive properties at behavioral and neuronal levels", as background; these were not tested in this paper.2 Funding was "a Russian President grant for leading scientific schools (5923.2014.4)", and the authors Ostrovskaya and Seredenin are affiliated with the State Zakusov Institute of Pharmacology, where the paper says noopept was designed.2 The saved text contains no passage on limitations; the work is in cultured cells, and the paper does not report a measurement in people.2

Other findings reported in the 2002 review

The 2002 Russian review attributes the drug's action to "the antioxidant effect, the antiinflammatory action, and the ability to inhibit the neurotoxicity of excess calcium and glutamate", and reports an "additional selective anxiolytic action", all from experimental investigations.4 The review also reports that activity "is retained both upon parenteral introduction and upon peroral administration", described as a principal advantage over more complex peptides.4 The record gives its authors as Ostrovskaia, Gudasheva, Voronina and Seredenin at the Institute of Pharmacology in Moscow, and states no funding.4

3

Half-life and pharmacokinetics

Values from the Milligram app's model.

Half-life
~0.5 h (app figure; no numeric human half-life in the sources)
Bioavailability
90% (app figure; no bioavailability figure in the sources)
Typical dose
10–30 mg/day (app figure)
Route
Oral
Time to peak
~0.3 h (app figure; no time to peak in the sources)

The second column holds the app's own figures, shown beside what the retrieved records report.

Table 3.1Half-life and pharmacokinetics5 rows
ParameterApp's figureReported in the records
Half-life~0.5 hNo numeric human half-life appears in the records retrieved; Boĭko and colleagues (2004) report slower elimination in humans than in rats and rabbits, with "considerable individual variability"1
Bioavailability90%No bioavailability figure for noopept appears in the records retrieved; the 2002 review reports that activity is retained after oral and parenteral administration in experiments4
Time to peak~0.3 hNo time to peak appears in the records retrieved
MetabolitesNot in the appRats: very intensive metabolism after intravenous dosing, with a hydroxylated metabolite; humans: "No drug metabolites are found in the human blood plasma, probably because of a relatively small dose and low concentration"1
Active metabolite in ratsNot in the appCycloprolyl glycine (CPG), which "differed significantly in its pharmacokinetic parameters from noopept" and had a similar spectrum of pharmacological action in rats5

The app's note gives a parent half-life under one hour and a one-compartment model. The 2004 paper is from the Laboratory of Pharmacokinetics at the Institute of Pharmacology in Moscow, with Gudasheva, Ostrovskaia and Voronina among its authors; its record states the species differences but no human dose, group size or numeric parameters, and no funding.1 Because the records retrieved give no human half-life, peak time or bioavailability, the app's three figures stand here without a figure from the sources beside them.

4

Human studies

Four PubMed records of Russian clinical reports were located (Amelin 2011, Bochkarev 2008, and two papers by Neznamov and Teleshova), and ClinicalTrials.gov returned 0 studies for "noopept". The records for two of them are short, and none of the four reports a registry number, randomisation or blinding in the text retrieved.

Table 4.1Human studies3 rows
Study and yearDesignPeopleDose and lengthMain result
Amelin and colleagues, Zh Nevrol Psikhiatr Im S S Korsakova, 20117Open prospective study with a control group; funding not stated in the record60 patients with stroke; control group size not statedNoopept 20 mg daily for 2 months (the record also states 12 months of treatment)MMSE and association tests improved after 2 months in the main group versus controls; global assessment showed "the mild improvement" in the main group and no change in controls7
Bochkarev and colleagues, Zh Nevrol Psikhiatr Im S S Korsakova, 20088Clinical and EEG study; design, comparator and funding not stated in the recordPatients with cerebral asthenic and cognitive disturbances caused by traumas or vascular brain diseases; n not statedNot stated in the recordHigher alpha and beta power and lower delta power on EEG; beta changes augmented in frontal and attenuated in occipital areas; EEG changes "less typical" in posttraumatic lesion8
Neznamov and Teleshova, Zh Nevrol Psikhiatr Im S S Korsakova, 2008, and Neurosci Behav Physiol, 200910,9Comparative study of noopept and piracetam, as the titles state; no further design detail in the recordsPatients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin, per the 2009 titleNot stated in the recordsNot stated in the records; PubMed holds no summary text for either

Deeper analysis: Amelin 2011, noopept in stroke patients

Amelin and colleagues (Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2011) describe "an open prospective study" of 60 patients with stroke treated with noopept "during 12 months", with cognitive function assessed "before and after treatment using neuropsychological tests".7 The record reports "the significant improvement of cognitive functions after 2 months in patients of the main group compared to the controls" on MMSE scores and lateral and categorical associations.7 The global assessment of efficacy showed "the mild improvement in the main group while no changes were found in the control group".7 The authors conclude that noopept at 20 mg daily for 2 months "improves cognitive functions in stroke patients and has a high level of safety".7 The record does not give the size or selection of the control group, the MMSE scores, an effect size, an interval or a p-value, the number of adverse events or dropouts, or what the 12-month period covers.7 The record states no funding, no limitations and no author ties to a sponsor, describes the study as open and prospective, and states no blinding.7

Deeper analysis: Bochkarev 2008, EEG study

Bochkarev, Teleshova, Siuniakov, Davydova and Neznamov studied EEG rhythms in "patients with cerebral asthenic and cognitive disturbances caused by traumas or vascular brain diseases".8 They report that noopept "caused the EEG changes characteristic of the action of nootropics", with alpha and beta power increased and delta power reduced.8 From the frequency and spatial pattern they conclude that noopept "exerts a nonspecific activation and anxyolytic effect", with changes most obvious in cerebral vascular diseases and "less typical" after trauma.8 The record gives no group size, dose, duration, comparator, adverse events, funding or limitations; an EEG change is a physiological measure, and the record reports no clinical outcome score.8 Two authors, Teleshova and Neznamov, also wrote the noopept and piracetam comparison listed above, which the Neznamov record places at the Clinical Psychopharmacology Laboratory of the V. V. Zakusov State Research Institute of Pharmacology.8,9

5

Doses reported in studies and on labels

DailyMed returned 0 labels for noopept, and no other regulator label was retrieved, so no label dose or strength is given.

Table 5.1Doses reported in studies and on labels4 rows
ReferenceSettingDose reported
Amelin and colleagues, 2011760 patients with stroke, open study20 mg daily for 2 months
Ostrovskaia and colleagues, 20024Tablets reported to be under clinical assessment in RussiaTablets of 5 mg and 10 mg
Cohen and colleagues, 2021610 supplements bought online in September 2019, each labelled with at least one of four piracetam analogs; omberacetam was detected in all 10Measured 5.1 ± 0.1 mg to 40.6 ± 0.4 mg per product; the authors give a typical pharmacologic dose of 10 mg
The appTypical dose entry10 to 30 mg/day, oral

The app's 10 to 30 mg/day range contains the 20 mg daily used by Amelin and colleagues; none of the records retrieved states where the range comes from.

Amelin and colleagues conclude that noopept at 20 mg daily "has a high level of safety", but their record reports no adverse event counts or dropouts.7 No adverse event data for noopept in people were found in the other human records retrieved.8,9 Cohen and colleagues list adverse effects "associated with" the five unapproved drugs in their study as a group, including "increased and decreased blood pressure, insomnia, agitation, dependence, sedation, hospitalization, and intubation", without attributing them to omberacetam specifically.6 They also state that "The health effects of consuming untested combinations of unapproved drugs at unpredictable dosages without clinician oversight in supplements are unknown".6

7

Regulatory and anti-doping status

Deeper analysis: Cohen 2021, omberacetam in supplements

Cohen and colleagues bought supplements listed in two databases in August 2019 as containing omberacetam, aniracetam, oxiracetam or phenylpiracetam, and analysed 10 of 12 products purchased in September 2019 by liquid chromatography-mass spectrometry.6 Omberacetam "was present in all 10 products" at 5.1 ± 0.1 mg to 40.6 ± 0.4 mg, against a typical pharmacologic dose of 10 mg stated by the authors.6 For products with drug quantities on the label, "75% (9/12) of declared quantities were inaccurate" across all drugs detected, not omberacetam alone, with accurate defined as within ±20% of the labelled quantity and actual quantities from 0% to 135% of the label amount.6 The authors state that the FDA "has issued a series of warning letters to companies selling picamilon, phenibut, omberacetam, and aniracetam supplements", and that US law "does not permit unapproved pharmaceuticals to be introduced as new ingredients into supplements".6 Their stated limitations are that "We tested only supplements labeled as containing 1 of the 4 piracetam analogs in 2 databases at one point in time" and that the results "are not generalizable to all dietary supplements labeled as containing a piracetam analog".6 The study reports "No targeted funding reported"; its disclosures state that I. Khan reported receiving grants from the US Food and Drug Administration, the National Institute of Health and the US Department of Agriculture and coordinates a conference that receives support for conference-related expenses from multiple supplement-related companies, and that Cohen has collaborated in research with NSF International, received compensation from UptoDate, and received research support from Consumers Union and PEW Charitable Trusts; none of the disclosures names a noopept manufacturer.6

WADA

The 2026 WADA Prohibited List text retrieved does not name noopept or omberacetam; it does name 4-phenylpiracetam among stimulants.11 Its S0 class prohibits at all times any pharmacological substance not addressed elsewhere on the list "with no current approval by any governmental regulatory health authority for human therapeutic use".11 The sources retrieved do not state how WADA classifies noopept, so whether S0 applies is not settled by them.11

8

What is not known

  • A human half-life, time to peak and oral bioavailability for noopept are not reported in the records retrieved, so the app's 0.5 h, 0.3 h and 90% stand without a figure from the sources beside them.
  • None of the human records retrieved states randomisation, placebo control or blinding; the PubMed records for the two Neznamov and Teleshova comparisons with piracetam hold no summary text, so their design is not known from the text, and the records give no p-values, intervals or adverse event counts.
  • The mechanism evidence (neurotrophin mRNA in rats, HIF-1 activity in HEK293 cells) has not been shown in people in the records retrieved.
  • The contents of noopept supplements varied from 5.1 to 40.6 mg per product in one 10-product sample, and the health effects of consuming untested combinations of unapproved drugs at unpredictable dosages are described by Cohen and colleagues as unknown.
What is the half-life of noopept?

The records retrieved give no numeric human half-life for noopept, and the app lists 0.5 hours.1 Boĭko and colleagues report that elimination in humans is slower than in rats and rabbits, with considerable individual variability.1

How long does noopept take to reach its peak level?

The records retrieved give no human time to peak, and the app lists about 0.3 hours.1

What is the bioavailability of noopept?

The records retrieved give no bioavailability figure for noopept, and the app lists 90%.4 A 2002 Russian review reports that the drug's activity in experiments is retained after oral and parenteral administration.4

What is noopept also called?

Noopept is also written GVS-111, and its chemical name is N-phenylacetyl-L-prolylglycine ethyl ester.3 Cohen and colleagues write "omberacetam (Noopept)" for the same drug.6

Is noopept banned by WADA?

The 2026 WADA Prohibited List text retrieved does not name noopept or omberacetam.11 Its S0 class covers substances with "no current approval by any governmental regulatory health authority for human therapeutic use", and the sources retrieved do not say how WADA applies it to noopept.11

Is noopept approved by the FDA?

Cohen and colleagues write that analogs of piracetam are not approved by the FDA for use in the US, and they describe omberacetam as available in Russia.6

What do the human studies of noopept show?

Amelin and colleagues reported improved MMSE scores and associations after 2 months of 20 mg daily in stroke patients compared with controls, in an open study of 60 patients.7 Bochkarev and colleagues reported EEG changes characteristic of nootropics, and the records for the Neznamov comparison with piracetam give no result.8,9

Is noopept the same as piracetam?

Noopept is not piracetam; Vakhitova and colleagues describe piracetam as the non-peptide prototype of noopept.2 In HEK293 cells, noopept at 10 μM increased HIF-1 DNA-binding activity while piracetam at 1 mM did not significantly affect any of the nine transcription factors tested.2

11

References

  1. Boĭko SS, et al. Interspecies differences of noopept pharmacokinetics. Eksp Klin Farmakol 2004;67(1):40-3. PMID 15079908
  2. Vakhitova YV, et al. Molecular Mechanism Underlying the Action of Substituted Pro-Gly Dipeptide Noopept. Acta Naturae 2016;8(1):82-9. PMC4837574
  3. Ostrovskaya RU, et al. Noopept stimulates the expression of NGF and BDNF in rat hippocampus. Bull Exp Biol Med 2008;146(3):334-7. PMID 19240853
  4. Ostrovskaia RU, et al. The original novel nootropic and neuroprotective agent noopept. Eksp Klin Farmakol 2002;65(5):66-72. PMID 12596521
  5. Boyko SS, et al. Pharmacokinetics of noopept and its active metabolite cycloprolyl glycine in rats. Biomed Khim 2018;64(5):455-8. PMID 30378564
  6. Cohen PA, et al. Five Unapproved Drugs Found in Cognitive Enhancement Supplements. Neurol Clin Pract 2021;11(3):e303-e307. PMC8382366
  7. Amelin AV, et al. Noopept in the treatment of mild cognitive impairment in patients with stroke. Zh Nevrol Psikhiatr Im S S Korsakova 2011;111(10 Pt 1):44-6. PMID 22500312
  8. Bochkarev VK, et al. Clinical and electroencephalographic characteristic of noopept in patients with mild cognitive impairment of posttraumatic and vascular origin. Zh Nevrol Psikhiatr Im S S Korsakova 2008;108(11):47-54. PMID 19008801
  9. Neznamov GG, Teleshova ES. Comparative studies of Noopept and piracetam in the treatment of patients with mild cognitive disorders in organic brain diseases of vascular and traumatic origin. Neurosci Behav Physiol 2009;39(3):311-21. PMID 19234797
  10. Neznamov GG, Teleshova ES. A comparative study of noopept and piracetam in mild and moderate cognitive impairment in patients with organic brain diseases of vascular and traumatic origin. Zh Nevrol Psikhiatr Im S S Korsakova 2008;108(3):33-42. PMID 18697252
  11. World Anti-Doping Agency. World Anti-Doping Code International Standard: Prohibited List 2026. WADA list